There are some encouraging interim results from the research and development activity by a UK-based company named ReNeuron Group (https://www.reneuron.com).They have been conducting phase 2 trials that implant human Retinal Progenitor Cells (hRPC). They are reporting a significant improvement in vision for people with a base level of photoreceptor function. The paradigm is interesting because it aims to establish new photoreceptor cells (vs. genetic modification rescue strategies) which offers promise for a large number of retinal dystrophies.
コメント